Discounted Cash Flow (DCF) Analysis Levered
AnPac Bio-Medical Science Co., Ltd. (ANPC)
$0.2422
+0.01 (+2.19%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.91 | 1.64 | 1.74 | 3.28 | 2.88 | 4.05 | 5.70 | 8.02 | 11.28 | 15.88 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -3.46 | -4.98 | -7.78 | -9.43 | -11.47 | -14.73 | -20.73 | -29.17 | -41.05 | -57.76 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.42 | -0.46 | -0.51 | -0.40 | -0.64 | -1.11 | -1.56 | -2.20 | -3.10 | -4.36 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -3.88 | -5.44 | -8.28 | -9.83 | -12.11 | -15.84 | -22.29 | -31.37 | -44.15 | -62.12 |
Weighted Average Cost Of Capital
| Share price | $ 0.2,422 |
|---|---|
| Beta | 1.315 |
| Diluted Shares Outstanding | 13.61 |
| Cost of Debt | |
| Tax Rate | 2.12 |
| After-tax Cost of Debt | 12.34% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 9.057 |
| Total Debt | 5.40 |
| Total Equity | 3.30 |
| Total Capital | 8.70 |
| Debt Weighting | 62.11 |
| Equity Weighting | 37.89 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.91 | 1.64 | 1.74 | 3.28 | 2.88 | 4.05 | 5.70 | 8.02 | 11.28 | 15.88 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.46 | -4.98 | -7.78 | -9.43 | -11.47 | -14.73 | -20.73 | -29.17 | -41.05 | -57.76 |
| Capital Expenditure | -0.42 | -0.46 | -0.51 | -0.40 | -0.64 | -1.11 | -1.56 | -2.20 | -3.10 | -4.36 |
| Free Cash Flow | -3.88 | -5.44 | -8.28 | -9.83 | -12.11 | -15.84 | -22.29 | -31.37 | -44.15 | -62.12 |
| WACC | ||||||||||
| PV LFCF | -14.26 | -18.06 | -22.88 | -28.98 | -36.70 | |||||
| SUM PV LFCF | -120.88 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 11.10 |
| Free cash flow (t + 1) | -63.37 |
| Terminal Value | -696.32 |
| Present Value of Terminal Value | -411.38 |
Intrinsic Value
| Enterprise Value | -532.25 |
|---|---|
| Net Debt | 3.92 |
| Equity Value | -536.17 |
| Shares Outstanding | 13.61 |
| Equity Value Per Share | -39.41 |